Semaglutide consistently reduced albuminuria in diabetic kidney disease, especially in patients with heavy protein loss, though eGFR results were variable.
Albuminuria consistently reducedAcross available studies, semaglutide most reliably reduced protein in the urine, a key driver of kidney disease progression
What the researchers found
Albuminuria was more consistently reduced by semaglutide than eGFR. The benefit was strongest in patients with macroalbuminuria (heavy protein loss). This suggests semaglutide may help slow the progression of diabetic kidney disease by reducing the protein that damages kidney filters.
However, the impact on eGFR was variable. Some studies showed improvement, others showed no change, and some showed decrease. This inconsistency could reflect differences in patient populations, disease severity, and follow-up duration.
Two case reports described acute kidney injury (AKI) associated with semaglutide, including one case of acute interstitial nephritis. This highlights the need for kidney monitoring during therapy, particularly in patients with advanced chronic kidney disease.
Why it matters
Diabetic kidney disease is the leading cause of kidney failure worldwide. Semaglutide's ability to reduce albuminuria is promising because albuminuria drives kidney damage progression. The FLOW trial (published separately) showed semaglutide reduced hard kidney outcomes by 24%. This review provides additional context about which kidney parameters improve and which patients may be at risk.
The numbers in context
- 6 studies included (2 case reports, 4 cohorts)
- Albuminuria: consistently reduced, especially macroalbuminuria
- eGFR: variable results across studies
- AKI: 2 case reports of acute kidney injury
- 1 case of acute interstitial nephritis
- Semaglutide: improved glycemic control and weight in all studies
How the study worked
Systematic review searching for all published evidence on semaglutide's renal effects in diabetic kidney disease. Six eligible studies were identified: 2 case reports and 4 cohort studies from diverse geographic locations. Primary outcomes were eGFR changes and albuminuria. Secondary outcomes included AKI incidence and other renal biomarkers.
Who was studied
Patients with diabetic kidney disease across 6 studies (2 case reports, 4 cohorts) from diverse geographic locations
What this study cannot tell us
Only 6 studies were found, and most were small cohorts or case reports. No randomized controlled trials were included (the FLOW trial was published separately). The case reports of AKI may represent rare events or confounded situations. The variable eGFR results could reflect the normal trajectory of diabetic kidney disease rather than drug effects. Geographic diversity may introduce confounding from different healthcare practices.
How to read the evidence
Rated moderate: systematic review methodology is sound, but only 6 studies were available (2 case reports, 4 cohorts) — no large RCTs were included.
When this study was published
Published in 2024, before the FLOW trial results. The evidence base has since strengthened significantly with the FLOW trial publication.
The bigger picture
Diabetic kidney disease is the leading cause of kidney failure worldwide. Semaglutide's ability to reduce albuminuria is promising because albuminuria drives disease progression. The FLOW trial published shortly after provides stronger confirmation.
Questions still open
- Why is albuminuria reduction more consistent than eGFR improvement?
- Are the rare AKI cases related to dehydration from GI side effects?
Common questions
Can semaglutide help diabetic kidney disease?
Can semaglutide harm the kidneys?
Read the original research
Assessing the Renal Outcomes of Semaglutide in Diabetic Kidney Disease: A Systematic Review.
Cureus, 16(7), e64038
Citation
Rehman, Shuja Ur; Kolanu, Nikhil Deep; Mushtaq, Muhammad Muaz; Ali, Husnain; Ahmed, Zeeshan; Mushtaq, Maham; Liaqat, Maryyam; Sarwer, Muhammad Asad; Bokhari, Syed Faqeer Hussain; Ahmed, Fazeel; Bakht, Danyal. (2024). Assessing the Renal Outcomes of Semaglutide in Diabetic Kidney Disease: A Systematic Review.. Cureus, 16(7), e64038. https://doi.org/10.7759/cureus.64038